{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:26:21Z","timestamp":1793820381234,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772824"],"award-info":[{"award-number":["81772824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372832"],"award-info":[{"award-number":["81372832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10549-018-05124-5","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T02:06:39Z","timestamp":1546481199000},"page":"639-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prevalence and characterization of ATM germline mutations in Chinese BRCA1\/2-negative breast cancer patients"],"prefix":"10.1007","volume":"174","author":[{"given":"Ziguo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-8107","authenticated-orcid":false,"given":"Yuntao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"issue":"10","key":"5124_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrm2514","volume":"9","author":"MF Lavin","year":"2008","unstructured":"Lavin MF (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9(10):759\u2013769. \n                    https:\/\/doi.org\/10.1038\/nrm2514","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"5124_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","volume":"14","author":"Y Shiloh","year":"2013","unstructured":"Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197\u2013210","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"5124_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","volume":"13","author":"N Tung","year":"2016","unstructured":"Tung N, Domchek SM, Stadler Z et al (2016) Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13(9):581\u2013588. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2016.90","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"5124_CR4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372(23):2243\u20132257. \n                    https:\/\/doi.org\/10.1056\/NEJMsr1501341","journal-title":"N Engl J Med"},{"issue":"13","key":"5124_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/jco.2015.63.7454","volume":"34","author":"ER Thompson","year":"2016","unstructured":"Thompson ER, Rowley SM, Li N et al (2016) Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 34(13):1455\u20131459. \n                    https:\/\/doi.org\/10.1200\/jco.2015.63.7454","journal-title":"J Clin Oncol"},{"issue":"10","key":"5124_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10):1721\u20131730. \n                    https:\/\/doi.org\/10.1002\/cncr.30498","journal-title":"Cancer"},{"issue":"9","key":"5124_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu C et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.0424","journal-title":"JAMA Oncol"},{"issue":"12","key":"5124_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","volume":"53","author":"MC Southey","year":"2016","unstructured":"Southey MC, Goldgar DE, Winqvist R et al (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53(12):800\u2013811. \n                    https:\/\/doi.org\/10.1136\/jmedgenet-2016-103839","journal-title":"J Med Genet"},{"issue":"11","key":"5124_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/humu.20415","volume":"27","author":"JL Bernstein","year":"2006","unstructured":"Bernstein JL, Teraoka S, Southey MC et al (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T> G and c.1066-6T> G (IVS10-6T> G) from the Breast Cancer Family Registry. Hum Mutat 27(11):1122\u20131128. \n                    https:\/\/doi.org\/10.1002\/humu.20415","journal-title":"Hum Mutat"},{"issue":"3","key":"5124_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/94.3.205","volume":"94","author":"G Chenevix-Trench","year":"2002","unstructured":"Chenevix-Trench G, Spurdle AB, Gatei M et al (2002) Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94(3):205\u2013215","journal-title":"J Natl Cancer Inst"},{"key":"5124_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31601","author":"J Li","year":"2018","unstructured":"Li J, Jing R, Wei H et al (2018) Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int J Cancer. \n                    https:\/\/doi.org\/10.1002\/ijc.31601","journal-title":"Int J Cancer"},{"issue":"1","key":"5124_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/annonc\/mdt421","volume":"25","author":"RC Bueno","year":"2014","unstructured":"Bueno RC, Canevari RA, Villacis RA et al (2014) ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas. Ann Oncol 25(1):69\u201375. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt421","journal-title":"Ann Oncol"},{"key":"5124_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13058-015-0575-2","volume":"17","author":"X Feng","year":"2015","unstructured":"Feng X, Li H, Dean M et al (2015) Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer. Breast Cancer Res 17:65. \n                    https:\/\/doi.org\/10.1186\/s13058-015-0575-2","journal-title":"Breast Cancer Res"},{"issue":"20","key":"5124_CR14","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.ccr-16-3227","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Meng H, Yao L et al (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer 23(20):6113\u20136119. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-3227","journal-title":"Clin Cancer"},{"issue":"6","key":"5124_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/annonc\/mdq612","volume":"22","author":"L Yao","year":"2011","unstructured":"Yao L, Liu Y, Li Z et al (2011) HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Ann Oncol 22(6):1326\u20131331. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq612","journal-title":"Ann Oncol"},{"issue":"5","key":"5124_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. \n                    https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"2","key":"5124_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1006\/mgme.2000.2998","volume":"70","author":"SG Becker-Catania","year":"2000","unstructured":"Becker-Catania SG, Chen G, Hwang MJ et al (2000) Ataxia-telangiectasia: phenotype\/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol Genet Metab 70(2):122\u2013133. \n                    https:\/\/doi.org\/10.1006\/mgme.2000.2998","journal-title":"Mol Genet Metab"},{"issue":"1","key":"5124_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/humu.20805","volume":"30","author":"M Mitui","year":"2009","unstructured":"Mitui M, Nahas SA, Du LT et al (2009) Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat 30(1):12\u201321. \n                    https:\/\/doi.org\/10.1002\/humu.20805","journal-title":"Hum Mutat"},{"issue":"2","key":"5124_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.onc.1201319","volume":"15","author":"Y Ziv","year":"1997","unstructured":"Ziv Y, Bar-Shira A, Pecker I et al (1997) Recombinant ATM protein complements the cellular A\u2013T phenotype. Oncogene 15(2):159\u2013167. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1201319","journal-title":"Oncogene"},{"issue":"2","key":"5124_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/humu.10158","volume":"21","author":"CH Buzin","year":"2003","unstructured":"Buzin CH, Gatti RA, Nguyen VQ et al (2003) Comprehensive scanning of the ATM gene with DOVAM-S. Hum Mutat 21(2):123\u2013131. \n                    https:\/\/doi.org\/10.1002\/humu.10158","journal-title":"Hum Mutat"},{"issue":"11","key":"5124_CR21","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1096\/fj.11-185546","volume":"25","author":"M Keimling","year":"2011","unstructured":"Keimling M, Volcic M, Csernok A et al (2011) Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways. FASEB J 25(11):3849\u20133860. \n                    https:\/\/doi.org\/10.1096\/fj.11-185546","journal-title":"FASEB J"},{"issue":"1","key":"5124_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/humu.21632","volume":"33","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Du L, Tunuguntla R et al (2012) Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia. Hum Mutat 33(1):198\u2013208. \n                    https:\/\/doi.org\/10.1002\/humu.21632","journal-title":"Hum Mutat"},{"issue":"19","key":"5124_CR23","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/jco.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32(19):2001\u20132009. \n                    https:\/\/doi.org\/10.1200\/jco.2013.53.6607","journal-title":"J Clin Oncol"},{"issue":"2","key":"5124_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jaci.2011.03.052","volume":"128","author":"R Micol","year":"2011","unstructured":"Micol R, Ben Slama L, Suarez F et al (2011) Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 128(2):382\u2013389.e381. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2011.03.052","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"5124_CR25","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1200\/jco.2009.25.5067","volume":"28","author":"CH Lin","year":"2010","unstructured":"Lin CH, Lin WC, Wang CH et al (2010) Child with ataxia telangiectasia developing acute myeloid leukemia. J Clin Oncol 28(14):e213\u2013e214. \n                    https:\/\/doi.org\/10.1200\/jco.2009.25.5067","journal-title":"J Clin Oncol"},{"issue":"3","key":"5124_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/ejhg.2011.196","volume":"20","author":"V Jacquemin","year":"2012","unstructured":"Jacquemin V, Rieunier G, Jacob S et al (2012) Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations. Eur J Hum Genet 20(3):305\u2013312. \n                    https:\/\/doi.org\/10.1038\/ejhg.2011.196","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"5124_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1155\/2006\/740493","volume":"22","author":"M Magliozzi","year":"2006","unstructured":"Magliozzi M, Piane M, Torrente I et al (2006) DHPLC screening of ATM gene in Italian patients affected by ataxia-telangiectasia: fourteen novel ATM mutations. Dis Mark 22(4):257\u2013264","journal-title":"Dis Mark"},{"issue":"8","key":"5124_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18(8):823\u2013832. \n                    https:\/\/doi.org\/10.1038\/gim.2015.166","journal-title":"Genet Med"},{"issue":"1","key":"5124_CR29","first-page":"40","volume":"59","author":"M Telatar","year":"1996","unstructured":"Telatar M, Wang Z, Udar N et al (1996) Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am J Hum Genet 59(1):40\u201344","journal-title":"Am J Hum Genet"},{"issue":"3","key":"5124_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G","volume":"92","author":"SN Teraoka","year":"2001","unstructured":"Teraoka SN, Malone KE, Doody DR et al (2001) Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 92(3):479\u2013487","journal-title":"Cancer"},{"issue":"3","key":"5124_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1098-1004(200009)16:3<232::aid-humu6>3.0.co;2-l","volume":"16","author":"K Laake","year":"2000","unstructured":"Laake K, Jansen L, Hahnemann JM et al (2000) Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia. Hum Mutat 16(3):232\u2013246. \n                    https:\/\/doi.org\/10.1002\/1098-1004(200009)16:3%3C232::aid-humu6%3E3.0.co;2-l","journal-title":"Hum Mutat"},{"issue":"8","key":"5124_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/humu.21034","volume":"30","author":"G Barone","year":"2009","unstructured":"Barone G, Groom A, Reiman A et al (2009) Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat 30(8):1222\u20131230. \n                    https:\/\/doi.org\/10.1002\/humu.21034","journal-title":"Hum Mutat"},{"issue":"3","key":"5124_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-016-3902-0","volume":"158","author":"J Zhang","year":"2016","unstructured":"Zhang J, Sun J, Chen J et al (2016) Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat 158(3):455\u2013462. \n                    https:\/\/doi.org\/10.1007\/s10549-016-3902-0","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"5124_CR34","first-page":"3325","volume":"63","author":"YR Thorstenson","year":"2003","unstructured":"Thorstenson YR, Roxas A, Kroiss R et al (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63(12):3325\u20133333","journal-title":"Cancer Res"},{"issue":"8","key":"5124_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ng1837","volume":"38","author":"A Renwick","year":"2006","unstructured":"Renwick A, Thompson D, Seal S et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873\u2013875. \n                    https:\/\/doi.org\/10.1038\/ng1837","journal-title":"Nat Genet"},{"issue":"11","key":"5124_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jnci\/dji141","volume":"97","author":"D Thompson","year":"2005","unstructured":"Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97(11):813\u2013822. \n                    https:\/\/doi.org\/10.1093\/jnci\/dji141","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"5124_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/jmedgenet-2017-104588","volume":"54","author":"B Decker","year":"2017","unstructured":"Decker B, Allen J, Luccarini C et al (2017) Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. J Med Genet 54(11):732\u2013741. \n                    https:\/\/doi.org\/10.1136\/jmedgenet-2017-104588","journal-title":"J Med Genet"},{"key":"5124_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2956","author":"HM Lu","year":"2018","unstructured":"Lu HM, Li S, Black MH et al (2018) Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncol. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2018.2956","journal-title":"JAMA Oncol"},{"issue":"2","key":"5124_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cge.12710","volume":"90","author":"NJ Os van","year":"2016","unstructured":"van Os NJ, Roeleveld N, Weemaes CM et al (2016) Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet 90(2):105\u2013117. \n                    https:\/\/doi.org\/10.1111\/cge.12710","journal-title":"Clin Genet"},{"issue":"5","key":"5124_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gepi.21971","volume":"40","author":"M Marabelli","year":"2016","unstructured":"Marabelli M, Cheng SC, Parmigiani G (2016) Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol 40(5):425\u2013431. \n                    https:\/\/doi.org\/10.1002\/gepi.21971","journal-title":"Genet Epidemiol"},{"issue":"11","key":"5124_CR41","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1158\/1055-9965.Epi-08-0414","volume":"17","author":"M Swift","year":"2008","unstructured":"Swift M, Lukin JL (2008) Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene. Cancer Epidemiol Biomark Prev 17(11):3188\u20133192. \n                    https:\/\/doi.org\/10.1158\/1055-9965.Epi-08-0414","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"18","key":"5124_CR42","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1200\/jco.2007.14.6613","volume":"26","author":"SL Dombernowsky","year":"2008","unstructured":"Dombernowsky SL, Weischer M, Allin KH et al (2008) Risk of cancer by ATM missense mutations in the general population. J Clin Oncol 26(18):3057\u20133062. \n                    https:\/\/doi.org\/10.1200\/jco.2007.14.6613","journal-title":"J Clin Oncol"},{"issue":"8","key":"5124_CR43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ng.3342","volume":"47","author":"H Helgason","year":"2015","unstructured":"Helgason H, Rafnar T, Olafsdottir HS et al (2015) Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet 47(8):906\u2013910. \n                    https:\/\/doi.org\/10.1038\/ng.3342","journal-title":"Nat Genet"},{"key":"5124_CR44","unstructured":"Daly MB, Pilarski R, Berry M et al NCCN Clinical practice guidelines in oncology. In: Genetic\/Familial high-risk assessment: breast and ovarian version1.2018. Accessed 17 June 2018"},{"issue":"1","key":"5124_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-018-0951-9","volume":"20","author":"AL Renault","year":"2018","unstructured":"Renault AL, Mebirouk N, Fuhrmann L et al (2018) Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Res 20(1):28. \n                    https:\/\/doi.org\/10.1186\/s13058-018-0951-9","journal-title":"Breast Cancer Res"},{"issue":"8","key":"5124_CR46","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.Mct-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R (2016) ATM Mutations in cancer: therapeutic implications. Mol Cancer Ther 15(8):1781\u20131791. \n                    https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0945","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"5124_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1535-7163.Mct-09-0872","volume":"9","author":"CT Williamson","year":"2010","unstructured":"Williamson CT, Muzik H, Turhan AG et al (2010) ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 9(2):347\u2013357. \n                    https:\/\/doi.org\/10.1158\/1535-7163.Mct-09-0872","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"5124_CR48","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4161\/cc.29212","volume":"13","author":"E Kubota","year":"2014","unstructured":"Kubota E, Williamson CT, Ye R et al (2014) Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 13(13):2129\u20132137. \n                    https:\/\/doi.org\/10.4161\/cc.29212","journal-title":"Cell Cycle"},{"key":"5124_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1756-9966-32-95","volume":"32","author":"MS Gilardini Montani","year":"2013","unstructured":"Gilardini Montani MS, Prodosmo A, Stagni V et al (2013) ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 32:95. \n                    https:\/\/doi.org\/10.1186\/1756-9966-32-95","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"5124_CR50","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","volume":"116","author":"VJ Weston","year":"2010","unstructured":"Weston VJ, Oldreive CE, Skowronska A et al (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578\u20134587. \n                    https:\/\/doi.org\/10.1182\/blood-2010-01-265769","journal-title":"Blood"},{"issue":"33","key":"5124_CR51","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/jco.2014.60.0320","volume":"33","author":"YJ Bang","year":"2015","unstructured":"Bang YJ, Im SA, Lee KW et al (2015) Randomized, double-blind phase II trial with prospective classification by atm protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 33(33):3858\u20133865. \n                    https:\/\/doi.org\/10.1200\/jco.2014.60.0320","journal-title":"J Clin Oncol"},{"issue":"18","key":"5124_CR52","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S et al (2015) DNA-Repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697\u20131708. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1506859","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-05124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-05124-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-05124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:47:12Z","timestamp":1577994432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-05124-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["5124"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-05124-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with Helsinki Declaration, and was approved by the Research Ethics Committee of Peking University Cancer Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}